The management of axillary lymph nodes in breast cancer is continually evolving. Recent data now support omitting axillary lymph node dissection (ALND) in most patients with metastases in up to two ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

MIAMI BEACH -- The surgical dogma favoring axillary dissection in breast cancer continues to give way to more selective data-driven strategies that allow more women to avoid axillary surgery, an ...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Previous trials have shown that omission of axillary-lymph-node dissection does not appear to affect important outcomes. New research findings extend those findings and are summarized in a short video ...